NASDAQ:APLS 30 October 2025

Apellis Shares Disappear After Biogen’s $5.6 Billion Buy—One Play Left

Apellis Pharmaceuticals is off the Nasdaq tape now that Biogen has finished its buyout. The focus moves to Biogen and if it can pull enough revenue from Syfovre and Empaveli to make the acquisition pay.

20 May 2026

Investment Opportunities·NASDAQ:APLS·NASDAQ:BIIB·Pharmaceutical News·Stock Market

Apellis Exits Nasdaq; $41 Takeover Wraps, One Bet Left

Biogen wrapped up its purchase of Apellis Pharmaceuticals last week, ending Apellis’ time as a listed company as its shares stopped trading on Nasdaq. Each Apellis holder will get $41 per share in cash and one contingent value right. The CVR will pay out if certain future sales targets are hit.

17 May 2026

NASDAQ:APLS·NASDAQ:BIIB·Stock Market

Biogen Closes Apellis Deal; APLS Leaves Nasdaq As $5.6 Billion Rare-Disease Bet Begins

Biogen said Thursday it has wrapped up its purchase of Apellis Pharmaceuticals, bringing Apellis under its wing as a fully owned subsidiary. The deal takes Apellis off the Nasdaq as an independent biotech, and hands Biogen ownership of its two approved drugs, which join Biogen’s rare-disease division.

15 May 2026

NASDAQ:APLS·NASDAQ:BIIB·Pharmaceutical Industry·Stock Market

Apellis Pharmaceuticals Vanishes From Nasdaq as Biogen’s Rare-Disease Bet Takes Over

Biogen wrapped up its takeover of Apellis Pharmaceuticals on Thursday, bringing an end to Apellis’ time as an independent Nasdaq-listed biotech. With the Waltham, Massachusetts firm now a wholly owned Biogen subsidiary, Apellis shares stopped trading on Nasdaq following completion of the tender offer and merger.

14 May 2026

NASDAQ:APLS·NASDAQ:BIIB·Pharmaceuticals·Stock Market

Apellis Pharmaceuticals Stock Nears Biogen’s $5.6 Billion Bid for Syfovre and Empaveli

Shares of Apellis Pharmaceuticals hovered close to Biogen’s $41-per-share bid on Wednesday, following news of the $5.6 billion cash-and-contingent deal announced a day earlier. The stock last traded at $40.23 in the U.S. session.

1 April 2026

NASDAQ:APLS·NASDAQ:BIIB·Pharmaceuticals·Stock Market

Apellis Pharmaceuticals Jumps as Biogen Agrees $5.6 Billion Buyout

Biogen said Tuesday it’s acquiring Apellis Pharmaceuticals in a cash deal valued near $5.6 billion, offering Apellis shareholders $41 per share upfront and additional potential payouts depending on Syfovre sales milestones. Apellis stock shot up to $40.32 after the open; Biogen shares edged down to $178.25.

31 March 2026

NASDAQ:APLS·NASDAQ:BIIB·Stock Market

Apellis (APLS) stock slides 15% after $689 mln 2025 revenue preview at JPM conference

Apellis Pharmaceuticals shares dropped almost 15% Monday following the release of preliminary 2025 U.S. sales numbers ahead of its J.P. Morgan Healthcare Conference update. The move put the stock in focus as biotech firms roll out early guidance for the year.

12 January 2026

Earnings Reports·NASDAQ:APLS·Stock Market

Apellis stock jumps nearly 8% as investors look to JPM healthcare update

Apellis Pharmaceuticals shares rose nearly 8% on Wednesday, outperforming the broader market as traders positioned ahead of the company’s scheduled appearance at next week’s J.P. Morgan Healthcare Conference. investors.apellis.com

7 January 2026

NASDAQ:APLS·Stock Market

Apellis’ $458M Shocker: FDA Win, Analyst Buzz & 20% Stock Whiplash

Apellis Pharmaceuticals, a biotech focused on complement-mediated diseasesgurufocus.com, delivered standout financial results for the third quarter of 2025 – yet its stock took a beating. The company reported Q3 revenue of $458.6 million, more than doubling from $196.8 M in the same quarter last yearinvesting.com. This record top-line was boosted by a one-time $275 M licensing deal with partner Sobiinvesting.com, which paid Apellis upfront for future ex-U.S. royalties on Aspaveli. Thanks largely to this deal, Apellis swung to a net profit of $215.7 Mmarkets.businessinsider.com.

30 October 2025

NASDAQ:APLS·Stock Market

Apellis Shares Disappear After Biogen’s $5.6 Billion Buy—One Play Left

Apellis Exits Nasdaq; $41 Takeover Wraps, One Bet Left

Biogen Closes Apellis Deal; APLS Leaves Nasdaq As $5.6 Billion Rare-Disease Bet Begins

Apellis Pharmaceuticals Vanishes From Nasdaq as Biogen’s Rare-Disease Bet Takes Over

Apellis Pharmaceuticals Stock Nears Biogen’s $5.6 Billion Bid for Syfovre and Empaveli

Apellis Pharmaceuticals Jumps as Biogen Agrees $5.6 Billion Buyout

Apellis (APLS) stock slides 15% after $689 mln 2025 revenue preview at JPM conference

Apellis stock jumps nearly 8% as investors look to JPM healthcare update

Apellis’ $458M Shocker: FDA Win, Analyst Buzz & 20% Stock Whiplash

TechStock² Updates

Ondas Shares Drop 9.7% After Reporting $50.6 Million EBITDA Loss Despite $757 Million Backlog

IREN shares drop 12.5% after $4 billion AI contract announcements coincide with $703 million annual loss

Nvidia Stock Falls 4.6%, Erasing $251 Billion as Margin Guide Tests AI Rally

Flutter shares climb 7.1% as FanDuel’s $350 promotion puts spotlight on marketing spend

DraftKings Bonus Incentive Drives Marketing Costs to 22% of Revenue; Shares Gain 4.3%

SpaceX Starship Flight 14 Slips to September as $1.85 Trillion Valuation Awaits Orbital Test

PG&E Shares Drop 7.5% After Wildfire Liability Deal Fails, Wiping Out $3 Billion

Intel Stock Falls 2.9% as 14A Defect Gains Confront $2.1 Billion Foundry Loss

Ford Shares Slip 0.5% as Threat of Canada Tariffs Challenges 7.5x Earnings Valuation

Salesforce Shares Lift 1.6% on 2.3x Volume as AI Surge Tests Analyst Price Targets

Investment Disclaimer